ICCC Immucell Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ICCC

Price (delayed)

$10.02

Market cap

$91M

P/E Ratio

143.14

Dividend/share

N/A

EPS

$0.07

Enterprise value

$94.59M

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 22
Relative Profitability: Rel. Profitability: 40

ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense ®, providing ...

Highlights
ICCC's quick ratio is up by 41% year-on-year and by 9% since the previous quarter
Immucell's debt has decreased by 13% YoY and by 2.6% from the previous quarter
ICCC's EPS has surged by 200% since the previous quarter but it has dropped by 67% year-on-year
ICCC's gross profit is up by 17% YoY but it is down by 3% QoQ
The net income has dropped by 55% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://immucell.com
Peers: IDXX WOOF MRK ZTS

Key stats

What are the main financial stats of ICCC

ICCC stock price

How has the Immucell stock price performed over time
Intraday
0%
1 week
-0.69%
1 month
-9.97%
1 year
64.26%
YTD
62.93%
QTD
-0.3%

Financial performance

How have Immucell's revenue and profit performed over time
Revenue
$30.68M
Gross profit
$12.37M
Operating income
$3.87M
Net income
$787,373
Gross margin
40.3%
Net margin
2.6%
The operating income has soared by 123% year-on-year and by 55% since the previous quarter
The operating margin has surged by 107% year-on-year and by 50% since the previous quarter
Immucell's net margin has plunged by 58% YoY
The net income has dropped by 55% year-on-year

Price vs fundamentals

How does ICCC's price correlate with its fundamentals

Growth

What is Immucell's growth rate over time

Valuation

What is Immucell stock price valuation
P/E
143.14
P/B
2.89
P/S
2.96
EV/EBIT
110.81
EV/EBITDA
29.21
EV/Sales
3.08
ICCC's EPS has surged by 200% since the previous quarter but it has dropped by 67% year-on-year
The stock's P/B is 61% more than its 5-year quarterly average of 1.8 and 31% more than its last 4 quarters average of 2.2
The company's equity rose by 8% QoQ and by 5% YoY
The stock's P/S is 35% more than its last 4 quarters average of 2.2 and 23% more than its 5-year quarterly average of 2.4
Immucell's revenue has increased by 8% YoY and by 2.5% QoQ

Efficiency

How efficient is Immucell business performance
ICCC's return on sales has dropped by 56% year-on-year
The company's return on equity has shrunk by 56% YoY
The ROA has dropped by 54% year-on-year
ICCC's ROIC is down by 47% year-on-year

Dividends

What is ICCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICCC.

Financial health

How did Immucell financials performed over time
ICCC's quick ratio is up by 41% year-on-year and by 9% since the previous quarter
Immucell's current ratio has increased by 23% YoY
Immucell's debt is 60% less than its equity
The company's debt to equity fell by 17% YoY and by 9% QoQ
Immucell's debt has decreased by 13% YoY and by 2.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.